MétaCan
Menu
Back to cohort

Population kinetics assessment of limited small cell lung cancer (L-SCLC).

2022· article· en· W4286295221 on OpenAlexaff
David J. Stewart

Bibliographic record

VenueJournal of Clinical Oncology · 2022
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Research Studies
Canadian institutionsOttawa Hospital
Fundersnot available
KeywordsMedicinePopulationInternal medicineSurvival analysisArea under the curveProportional hazards modelProgression-free survivalNuclear medicineOncologyOverall survival

Abstract

fetched live from OpenAlex

e20602 Background: For most advanced malignancies, progression free survival (PFS) and overall survival (OS) curves approximate first order kinetics. 1 PFS and OS half-lives can be calculated by curve exponential decay nonlinear regression analysis (EDNLRA). Curve characteristics vary significantly with treatment and malignancy type. 1 On log-linear plots, PFS curves are significantly more likely to be convex for extensive SCLC than for other malignancies, with late acceleration of tumor growth after completion of 1 st line therapy. 1,2 Here we assess L-SCLC by EDNLRA. Methods: We used https://apps.automeris.io/wpd/ to digitize PFS curves from L-SCLC studies published from 1990 to 2021. We analyzed curves for study arms having > 50 patients. We used GraphPad Prism 7 for 1 and 2 phase decay EDNLRA as previously described. 1 We also constructed log-linear plots. Results: We analyzed 55 L-SCLC PFS curves from 34 published trials. Median PFS half-life was 15 months for studies published 1990 to 2010 vs 19.5 months for 2011 to 2021 (P = 0.003). This improvement over time might be explained in part by stage migration (eg, with PET scanning). Of 55 log-linear plots, 53 (96%) had an inflection to the right. The curve inflection indicates there are 2 distinct subpopulations: namely progressing patients vs cured patients. Of the 55 curves, 46 fit 2 phase decay EDNLRA models. Across these 46 2-phase decay curves, EDNLRA calculations indicated that the progressing subgroup comprised 86% of the total population and had a PFS half-life of 10.5 months. The cured subgroup accounted for the other 14% of the population, with a PFS half-life greater than 15 years. The proportion cured increased from a median of 12% for 1990-2010 studies to 22% for 2011-2021 studies (p = 0.01). Stage migration might again explain this difference. For patients who are progression-free at any time point, one can also use these EDNLRA data to calculate the proportion who would eventually progress in the future. Of those still progression free at 12, 24, 36, 48, 60 and 120 months, respectively, the proportion that would eventually progress would be 73%, 56%, 36%, 20%, 10%, and 0.2%. As with extensive SCLC, all 55 L-SCLC PFS log-linear curves displayed early convexity, with a downward inflection after a period of relative stability. This downward inflection occurred at a median of 4.4 months, in keeping with acceleration of progression after completion of planned systemic therapy. Conclusions: Population kinetic assessments permit calculation of probability of eventual progression for L-SCLC patients who remain progression-free at different time points after initiation of therapy. Of L-SCLC patients who remain progression-free at 60 months, approximately 10% are nevertheless destined to eventually relapse. References: Stewart DJ et al. Crit Rev Oncol Hematol. 2020;153:103039. Stewart DJ et al. Proc American Soc Clin Oncol 2020. Abstract # e21101.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.029
Threshold uncertainty score0.557

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.178
GPT teacher head0.568
Teacher spread0.389 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicLung Cancer Research StudiesFrench-language works237,207